The overall goal of the Pharmacology and Analytical Center Facility is to provide the broad base of sophistical analytical equipment and expertise in pharmacology and medicinal chemistry required for preclinical and clinical investigations of anti-cancer drugs and related therapies. This goal will be accomplished by focusing on three aims. First, the Pharmacology and Analytical Center Facility will enable expanded analytical support for basic and clinical scientists at The University of Texas M.D. Anderson Cancer Center. This support will include access to instruments for nuclear magnetic resonance (NMR), liquid chromatography (LC)/mass spectrometry (MS), gas chromatography (GC), GC/MS, and high- performance liquid chromatography (HPLC). Support will also include assistance with the verification of structural identify, purification, and determination of stability of drugs and drug metabolites, as well as assistance with developing assays, solving proof-of-identity problems, and developing validation procedures. Second, scientists running the Pharmacology and Analytical Center Facility will provide a resource for investigators seeking pharmacokinetic and pharmacodynamic information on specific compounds and knowledge off how to best use such information for optimal protocol design, dose adjustments to increase efficacy or decrease toxicity, and similar clinical problems. Finally, the Pharmacology and Analytical Center Facility will provide a pharmacology resource for information about and techniques for studying nucleic acid components, such as bases, nucleosides, nucleotides, and oligonucleotides. This services will also include quantitation of the radioactivity associated with proteins, and Betascope and radiometric flow analytical instrumentation will be available. The analytical instruments of the Pharmacology and Analytical Center Facility are conveniently housed on the same (seventh) floor of M.D. Anderson Cancer Center in laboratories run by Director Robert Newman and co-directors William Plunkett, Timothy Madden, and David Farquhar. The equipment and analytical support to be provided by the facility are deemed critical for the success of many of the disease site- and them-specific programs proposed in this application. Formation of the Pharmacology and Analytical Center Facility will augment the ability of M.D. Anderson investigators to collaborate on studies involving pharmacologic analyses.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
United States
Zip Code
Moore, Amanda R; Ran, Leili; Guan, Youxin et al. (2018) GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma. Cell Rep 22:2455-2468
Weiss, Anna; Menen, Rhiana S; Lin, Heather Y et al. (2018) Factors associated with improved outcomes for metastatic inflammatory breast cancer patients. Breast Cancer Res Treat 169:615-623
Fountzilas, Elena; Tsimberidou, Apostolia M (2018) Overview of precision oncology trials: challenges and opportunities. Expert Rev Clin Pharmacol 11:797-804
Riquelme, Erick; Maitra, Anirban; McAllister, Florencia (2018) Immunotherapy for Pancreatic Cancer: More Than Just a Gut Feeling. Cancer Discov 8:386-388
Lee, Chi Hyun; Ning, Jing; Shen, Yu (2018) Analysis of restricted mean survival time for length-biased data. Biometrics 74:575-583
Fu, Jack B; Morishita, Shinichiro; Yadav, Rajesh (2018) Changing Paradigms in the Rehabilitation of Inpatients with Brain Tumors. Curr Phys Med Rehabil Rep 6:115-120
Amaria, Rodabe N; Prieto, Peter A; Tetzlaff, Michael T et al. (2018) Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol 19:181-193
Pal, Navdeep; Broaddus, Russell R; Urbauer, Diana L et al. (2018) Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device. Obstet Gynecol 131:109-116
Caceres, S; Monsalve, B; Peña, L et al. (2018) In vitro and in vivo effect of flutamide on steroid hormone secretion in canine and human inflammatory breast cancer cell lines. Vet Comp Oncol 16:148-158
Huang, Lu; Malu, Shruti; McKenzie, Jodi A et al. (2018) The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression. Clin Cancer Res 24:3366-3376

Showing the most recent 10 out of 12418 publications